AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19
|
14 April 2020 |
AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19
|
24 March 2020 |
AstraZeneca completes divestment agreement with Atnahs Pharma for established hypertension medicines
|
02 March 2020 |
AstraZeneca divests global rights to Movantik
|
25 February 2020 |
AstraZeneca divests rights to established hypertension medicines
|
27 January 2020 |
Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
|
20 January 2020 |
Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer
|
15 January 2020 |
Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
|
06 January 2020 |
Lynparza approved in the US as a 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
|
31 December 2019 |
Lynparza recommended by FDA advisory committee for 1st-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
|
18 December 2019 |